Loading
A phase 1/2 trial of ENV-501 in melanoma and non-small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT06956690 by Hummingbird Bioscience, with 180 participants planned, started 2025-12-17 and due to reach its primary completion in 2027-07. Interventions recorded: ENV-501. Conditions listed: Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/